Amneal Pharmaceuticals, Inc. (AMRX) News
Follow Amneal Pharmaceuticals, Inc. (AMRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Amneal Pharmaceuticals Reports Quarterly Results Through September 30
EQUITY | Nov 03, 2026, 02:32 PM UTC
M
Amneal Reports Q3 2026 Results and Raises Full-Year Guidance
Amneal reported third-quarter revenue of $863 million, up 10% year over year; adjusted EBITDA rose 30% to $207 million and adjusted diluted EPS increased 53% to $0.26. It raised full-year 2026 guidance for revenue, adjus
EQUITY | Nov 03, 2026, 12:33 PM UTC
M
Amneal Pharmaceuticals Q3 Adjusted Earnings and Revenue Rise
Amneal Pharmaceuticals reported rises in adjusted earnings and revenue for Q3.
EQUITY | Nov 03, 2026, 11:36 AM UTC
M
Amneal Pharmaceuticals Raises FY26 Revenue View to $3.15B–$3.25B
EARNINGS | Nov 03, 2026, 11:15 AM UTC
M
Amneal Expects 2026 Adjusted EPS of $1.04–$1.08
Amneal Pharmaceuticals expects 2026 adjusted EPS of $1.04–$1.08, versus a FactSet estimate of $1.03.
EARNINGS | Nov 03, 2026, 11:14 AM UTC
M
Amneal Pharmaceuticals Reports Third-Quarter Revenue of $862.7M
EQUITY | Nov 03, 2026, 11:14 AM UTC
M
Amneal Reports Q3 2026 Revenue of $863 Million, Updates Guidance
Amneal reported a GAAP net loss of $22 million and a diluted loss per share of $(0.06). Adjusted EBITDA was $207 million, with adjusted diluted EPS of $0.26.
EQUITY | Nov 03, 2026, 11:12 AM UTC
M
Amneal Reports Third-Quarter 2026 Financial Results
EQUITY | Nov 03, 2026, 11:03 AM UTC
M
Amneal Q3 Adjusted EPS USD 0.26 vs. IBES Estimate USD 0.23
EARNINGS | Nov 03, 2026, 11:03 AM UTC
M
US Estrogen Shortage Worsens as Demand Shifts to Alternatives
Pharmacies report supply problems with estrogen injections and vaginal creams. Viatris has added shifts at its Vermont plant and plans an additional production line to meet demand.
EQUITY | Oct 28, 2026, 10:05 AM UTC
M
Amneal Pharmaceuticals Q3 Revenue Estimate and EPS Forecast
Amneal Pharmaceuticals is expected to report Q3'26 results before the market opens on November 3. Revenue and EPS estimates were provided.
EQUITY | Oct 27, 2026, 11:02 AM UTC
M
Amneal to report Q3 2026 results on Nov. 3, 2026
EQUITY | Oct 08, 2026, 12:01 PM UTC
L
Amneal Pharmaceuticals Price Target Announced at $27.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) Amneal Pharmaceuticals Initiated at Outperform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:20 PM UTC
M
Ipsen shares drop after FDA approval of U.S. generic rival
Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected.
EQUITY | Sep 21, 2026, 10:02 AM UTC
L
AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection
AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection
REGULATION | Sep 18, 2026, 08:01 PM UTC
L
Leerink Partners sets $23.00 share price target for Amneal Pharmaceuticals
Leerink Partners announced a $23.00 per-share price target for Amneal Pharmaceuticals, according to ratings actions cited by Benzinga.
EQUITY | Sep 09, 2026, 03:12 PM UTC
H
Amneal Completes Acquisition of Kashiv BioSciences
Amneal acquires Kashiv BioSciences
MNA | Aug 10, 2026, 12:01 PM UTC
L
AMRX -6% after Q2 results
AMRX -6% after Q2 results
EARNINGS | Jul 30, 2026, 01:34 PM UTC
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
L
AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M
AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M
EARNINGS | Jul 30, 2026, 10:02 AM UTC
L
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050
Amneal Pharmaceuticals (NASDAQ: AMRX ) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200 bil
EARNINGS | Jul 30, 2026, 10:01 AM UTC
L
AMRX - Amneal Reports Second Quarter 2026 Financial Results
AMRX - Amneal Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 10:00 AM UTC
L
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
EQUITY | Jul 22, 2026, 12:51 PM UTC
L
AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch n
AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch new iohexol injection products in Q3 2026
REGULATION | Jul 17, 2026, 12:00 PM UTC
H
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc
MACRO | Jun 30, 2026, 02:17 PM UTC
L
US FDA selects seven participants for precheck pilot program to advance US drug manufacturing
Names include Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin and Regeneron
REGULATION | Jun 29, 2026, 08:34 PM UTC